Table 3.
Clinical response to 2nd-line therapy.
| Osimertinib N =58 (%) |
Nonosimertinib N = 44 (%) |
P value | |
|---|---|---|---|
| CR | 0 | 0 | 0.001 |
| PR | 30 (51.7%) | 10 (22.7%) | |
| SD | 26 (44.8) | 24 (54.5%) | |
| PD | 2 (3.5%) | 10 (22.7%) | |
| RR (%) | 51.7 | 22.7 | |
| DCR (%) | 96.5 | 77.3 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RR, response rate; DCR, disease control rate.